

Cancer Therapies Treatment Selector (1)

Charts revised December 2021. Full information available at www.hiv-druginteractions.org

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

	ATV/c	ATV/r	DRV/c	DRV/r	LPV/r	DOR	EFV	ETV	NVP	RPV oral	FTR	MVC	BIC/F/TAF	CAB oral	CAB/RPV	DTG	EVG/c/F/TAF	EVG/c/F/TDF	RAL	FTC/TAF	FTC/TDF	TDF	
Anti-tumour Antibiotics																							
Bleomycin	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	
Daunorubicin	↔ a	↔ a	↔	↔	↔ a	↔	↔	↔	↔	↔ a	↑ a	↔	↔	↔	↔ a	↔	↔	↔	↔	↔	↔	↔	
Doxorubicin	↔ a	↔ a	↔	↔	↔ a	↔	↔	↔	↔	↔ a	↑ a	↔	↔	↔	↔ a	↔	↔	↔	↔	↔	↔	↔	
Epirubicin	↔ a	↓ a	↔	↓	↓ a	↔	↑	↔	↔	↔ a	↔ a	↔	↔	↔	↔ a	↔	↔	↔	↔	↔	↔	↔	
Alkylating Agents																							
Carboplatin	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔ b,c	↔	↔	↔ b,c	↔ b,c	
Chlorambucil	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	
Cisplatin	↑	↑	↑	↑	↑	↔	↔	↔	↔	↔	↔	↔	↑↑ d	↔	↔	↔	↔	↑↑ b,d	↑↑ b,d	↔	↑↑ b,d	↑↑ b,d	↔ b
Cyclophosphamide	↓ e	↓ e	↓ e	↓ e	↓ e	↔	↓ f	↓ f	↓ f	↔	↔	↔	↔	↔	↔	↔	↔	↓ e	↓ e	↔	↔	↔	
Dacarbazine	↔	↓ e	↔	↓ e	↓ e	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↑↑ g	↔	↔	↑↑ g	↑↑ g
Dactinomycin	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	
Ifosfamide	↑ h	↑ h	↑ h	↑ h	↑ h	↓	↓ f	↓ f	↓ f	↓	↓	↓	↑ or ↓	↔	↓	↔	↔	↑ b,h	↑ b,h	↔	↔ b	↔ b	↔ b
Oxaliplatin	↔ ♥	↔ ♥	↔	↔	↔ ♥	↔	↔	↔	↔	↔ ♥	↔ ♥	↔	↔ j	↔	↔ ♥	↔ j	↔	↔ b	↔	↔	↔ b	↔ b	
Procarbazine	↔	↓ e	↔	↓ e	↓ e	↔	↓ e	↔	↓ e	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	
Antimetabolite Agents																							
Capecitabine	↔ ♥	↔ ♥	↔	↔	↔ ♥	↔	↔	↔	↔	↔ ♥	↔ ♥	↔	↑?	↔	↔ ♥	↔	↑?	↑?	↔	↑?	↑?	↑?	
Cytarabine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	
Fluorouracil	↔ ♥	↔ ♥	↔	↔	↔ ♥	↔	↔	↔	↔	↔ ♥	↔ ♥	↔	↑?	↔	↔ ♥	↔	↑?	↑?	↔	↑?	↑?	↑?	
Gemcitabine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	
Mercaptopurine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	
Methotrexate	↔ k	↔ k	↔ k	↔ k	↔ k	↔ k	↔ k	↔ k	↔ k	↔ k	↑? k	↔ k	↔ k	↑? k	↑? k	↔ k	↔ k	↑ b,k	↔ k	↔ k	↑ b,k	↑ b,k	
Plant Alkaloids																							
Docetaxel	↑	↑	↑	↑	↑	↔	↓	↓	↓	↑?	↑	↑?	↔	↔	↑?	↔	↑	↑	↔	↔	↔	↔	
Etoposide	↑	↑	↑	↑	↑	↔	↓	↓	↓	↔	↔	↔	↔	↔	↔	↔	↑	↑	↔	↔	↔	↔	
Irinotecan	↑ l,m	↑ l,m	↑ l	↑ l	↑ l	↔	↓ n	↓ n	↓ n	↔	↑	↔	↔	↔	↔	↔	↑ l	↑ l	↔	↔	↔	↔	
Paclitaxel	↑	↑	↑	↑	↑	↓	↑	↓ ↓	↔	↓	↑	↓	↓ o	↔	↓	↓	↑	↑	↓	↔	↔	↔	
Vinblastine	↑	↑	↑	↑	↑	↓	↓	↓ ↓	↓	↓	↓	↓	↓ o	↔	↓	↓	↑	↑	↓	↔	↔	↔	
Vincristine	↑	↑	↑	↑	↑	↔	↓	↓	↓	↔	↔	↔	↔	↔	↔	↔	↑	↑	↔	↔	↔	↔	

Interactions with CAB/RPV long acting injections
Pharmacokinetic interactions shown are mostly with RPV. QT interactions shown are with RPV.

Interactions with Ibalizumab
None

Interactions with Abacavir (ABC), Lamivudine (3TC) or Zidovudine (ZDV)

ABC: ABC may compete for the metabolic pathways of capecitabine and fluorouracil (clinical relevance unknown).
3TC: 3TC may compete for the metabolic pathways of capecitabine and fluorouracil (clinical relevance unknown).
3TC: Concentrations of cisplatin and 3TC could increase if coadministered. Furthermore, cisplatin may impair renal function. Closely monitor creatinine clearance.
3TC: Concentrations of oxaliplatin and 3TC could increase if coadministered. Monitor side effects.
ZDV: Potential additive haematological toxicity with capecitabine, carboplatin, chlorambucil, cisplatin, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, docetaxel, doxorubicin, epirubicin, etoposide, fluorouracil, gemcitabine, ifosfamide, irinotecan, mercaptopurine, methotrexate, oxaliplatin, paclitaxel, procarbazine, vinblastine, vincristine.

Colour Legend

- No clinically significant interaction expected.
- These drugs should not be coadministered.
- Potential interaction which may require a dose adjustment or close monitoring.
- Potential interaction predicted to be of weak intensity. No *a priori* dosage adjustment is recommended.

Text Legend

- ↑ Potential increased exposure of the cancer drug
- ↓ Potential decreased exposure of the cancer drug
- ↔ No significant effect
- ♥ One or both drugs may cause QT and/or PR prolongation. ECG monitoring is advised if coadministered with atazanavir or lopinavir.
- ↑ Potential increased exposure of HIV drug
- ↓ Potential decreased exposure of HIV drug
- o Rilpivirine and fostemsavir were shown to prolong the QT interval at supratherapeutic doses. Caution is advised with rilpivirine. ECG monitoring is advised with fostemsavir and drugs with a known QT prolongation risk.

Notes

- a Cytostatic agent may induce cardiac toxicity including arrhythmias and/or non-specific ECG abnormalities; caution is warranted in presence of other drugs with potential effects on PR and QT intervals.
- b Potential additive nephrotoxicity
- c The cytostatic agent may impair renal function: monitor creatinine clearance and adjust NRTI dosage accordingly (may require a change from a single tablet regimen).
- d Coadministration may increase concentrations of cisplatin and FTC. Close monitoring of renal function is recommended.
- e Concentrations of parent drug decreased but concentrations of the active metabolite increased.
- f Concentrations of parent drug decreased but concentrations of the active metabolite and toxic metabolite increased.
- g Concentrations of dacarbazine and tenofovir may increase. Close monitoring of renal function is recommended.
- h Concentrations of parent drug increased but concentrations of the active metabolite decreased which may result in decreased efficacy.
- i Coadministration may affect bictegravir concentrations. In addition, ifosfamide and tenofovir alafenamide may show additive renal toxicity.
- j The oxaliplatin effect may be potentially antagonised due to its reduced entry into the tumour cell arising from the inhibition of OCT2.
- k Use in HIV patients is contraindicated by some manufacturers.
- l Concentrations of SN-38 (active metabolite) increased.
- m Coadministration is contraindicated in the atazanavir US product label, but the European product label recommends patients should be closely monitored for adverse reactions related to irinotecan.
- n Conversion of SN-38 to inactive metabolite increased.
- o Coadministration may decrease bictegravir concentrations, but no effect on emtricitabine or tenofovir alafenamide is expected.

Abbreviations ATV atazanavir DRV darunavir LPV lopinavir /c cobicistat /r ritonavir DOR doravirine EFV efavirenz ETV etravirine NVP nevirapine RPV rilpivirine FTR fostemsavir MVC maraviroc BIC bictegravir CAB Cabotegravir DTG dolutegravir EVG elvitegravir RAL raltegravir F or FTC emtricitabine TAF tenofovir alafenamide TDF tenofovir-DP

© Liverpool Drug Interactions Group, University of Liverpool, Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF.
We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Cancer Therapies Treatment Selector (2)

Charts revised December 2021. Full information available at www.hiv-druginteractions.org

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

	ATV/c	ATV/r	DRV/c	DRV/r	LPV/r	DOR	EFV	ETV	NVP	RPV oral	FTR	MVC	BIC/F/TAF	CAB oral	CAB/RPV	DTG	EVG/c/F/TAF	EVG/c/F/TDF	RAL	FTC/TAF	FTC/TDF	TDF
Tyrosine Kinase Inhibitors																						
Dasatinib	↑♥	↑♥	↑	↑	↑♥	↔	↓	↓	↓	↑♥	↔♥	↑	↔	↔	↑♥	↔	↑	↑	↔	↔	↔	↔
Erlotinib	↑	↑	↑	↑	↑	↔	↓	↓	↓	↔	↔	↔	↔	↔	↔	↔	↑	↑	↔	↔	↔	↔
Gefitinib	↑	↑	↑	↑	↑	↔	↓	↓	↓	↔	↔	↔	↔	↔	↔	↔	↑	↑	↔	↔	↔	↔
Imatinib	↑♥	↑♥	↑♥	↑♥	↑♥	↑	↓↑	↓↑	↓↑	↑♥	↑♥	↑	↔	↔	↑♥	↔	↑♥	↑♥	↔	↔	↔	↔
Lapatinib	↑♥	↑♥	↑♥	↑♥	↑♥	↔	↓	↓	↓	↑♥	↔♥	↑	↔	↔	↑♥	↔	↑♥	↑♥	↔	↔	↔	↔
Nilotinib	↑♥	↑♥	↑♥	↑♥	↑♥	↑	↓↑	↓↑	↓↑	↑♥	↔♥	↑	↓ _a	↔	↑♥	↔	↑♥	↑♥	↔	↔	↔	↔
Pazopanib	↑♥	↑♥	↑♥	↑♥	↑♥	↔	↓	↓	↓	↑♥	↔♥	↑	↔	↔	↑♥	↔	↑♥	↑♥	↔	↔	↔	↔
Sunitinib	↑♥	↑♥	↑♥	↑♥	↑♥	↔	↓	↓	↓	↔♥	↔♥	↔	↔	↔	↔♥	↔	↑♥	↑♥	↔	↔	↔	↔
Others																						
Abiraterone	↔♥	↔♥	↔	↔	↔♥	↔	↓	↓	↓	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Avelumab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Bortezomib	↑♥	↑♥	↑	↑	↑♥	↔	↓	↓	↓	↔♥	↔♥	↔	↔	↔	↔	↔	↑	↑	↔	↔	↔	↔
Brentuximab vedotin	↑ _b	↑ _b	↑ _b	↑ _b	↑ _b	↔	↓ _c	↓ _c	↓ _c	↔	↔	↔	↔	↔	↔	↔	↑ _x	↑ _x	↔	↔	↔	↔
Cetuximab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Enzalutamide	↓	↓	↓	↓	↓	↓	↑	↓	↓	↓	↓	↓ _d	↓	↓	↓	↓	↓ _e	↓	↓ _f	↓ _g	↔	↔
Everolimus	↑	↑	↑	↑	↑	↔	↓	↓	↓	↔	↔	↔	↔	↔	↔	↔	↑	↑	↔	↔	↔	↔
Polatuzumab vedotin	↑ _b	↑ _b	↑ _b	↑ _b	↑ _b	↔	↓ _c	↓ _c	↓ _c	↔	↔	↔	↔	↔	↔	↔	↑ _b	↑ _b	↔	↔	↔	↔
Sorafenib	↔ _h	↔ _h	↔ _h	↔ _h	↔ _h	↔	↓	↓	↓	↔♥	↔♥	↔	↔	↔	↔	↔	↔ _h	↔ _h	↔	↔	↔	↔
Tamoxifen	↑ _i	↑ _i	↑ _i	↑ _i	↑ _i	↓	↓	↓	↓	↓♥	↔♥	↓	↓ _a	↔	↓♥	↔	↑ _i	↑ _i	↔	↔	↔	↔
Temsirolimus	↑	↑	↑	↑	↑	↔	↓ _j	↓ _j	↓ _j	↑	↔	↑	↔	↔	↑	↔	↑	↑	↔	↔	↔	↔
Trastuzumab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Trastuzumab emtansine	↑ _k	↑ _k	↑ _k	↑ _k	↑ _k	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↑ _k	↑ _k	↔	↔	↔	↔

Interactions with CAB/RPV long acting injections
Pharmacokinetic interactions shown are mostly with RPV. QT interactions shown are with RPV.

Interactions with Ibalizumab
None

Interactions with Abacavir (ABC), Lamivudine (3TC) or Zidovudine (ZDV)
ABC: Enzalutamide may decrease ABC concentrations, although to a limited extent. No a priori dose adjustment is required.
3TC: No clinically relevant interactions expected.
ZDV: Potential additive haematological toxicity with bortezomib, imatinib, trastuzumab, trastuzumab emtansine.

Colour Legend

- No clinically significant interaction expected.
- These drugs should not be coadministered.
- Potential interaction which may require a dose adjustment or close monitoring.
- Potential interaction predicted to be of weak intensity. No *a priori* dosage adjustment is recommended.

Text Legend

- ↑ Potential increased exposure of the cancer drug
- ↓ Potential decreased exposure of the cancer drug
- ↔ No significant effect
- ↔♥ One or both drugs may cause QT and/or PR prolongation. ECG monitoring is advised if coadministered with atazanavir or lopinavir. Rilpivirine and fostemsavir were shown to prolong the QT interval at supratherapeutic doses. Caution is advised with rilpivirine. ECG monitoring is advised with fostemsavir and drugs with a known QT prolongation risk.
- ↔♥ Potential QT and/or PR prolongation due to the cytostatic agent. Use with caution; ECG monitoring recommended.
- ↑↑ Potential increased exposure of HIV drug
- ↓↓ Potential decreased exposure of HIV drug

Notes

- a** Coadministration may decrease bicitravir concentrations, but no effect on emtricitabine or tenofovir alafenamide is expected.
- b** Brentuximab vedotin and polatuzumab vedotin are antibody-drug conjugates comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent and a substrate of CYP3A4 and P-gp. Coadministration may increase concentrations of MMAE and the incidence of neutropenia. Patients should be closely monitored for toxicities.
- c** Brentuximab vedotin and polatuzumab vedotin are antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent and a substrate of CYP3A4 and P-gp. Coadministration may decrease concentrations of MMAE but no a priori dose adjustment is necessary as the contribution of free MMAE to efficacy is minimal.
- d** Consider increasing maraviroc to 600 mg twice daily in presence of enzalutamide. Enzalutamide has a long half-life (5.8 days), therefore the maraviroc dose should be kept at 600 mg twice daily for a minimum of 2 weeks (but preferably 4 weeks) following cessation of enzalutamide due to the persisting inducing effect upon discontinuation of a strong inducer.
- e** Dolutegravir should be administered at 50 mg twice daily in the absence of integrase class resistance. In the presence of integrase class resistance this combination should be avoided. Enzalutamide has a long half-life (5.8 days), therefore the dolutegravir dose should be kept at 50 mg twice daily for a minimum of 2 weeks (but preferably 4 weeks) following cessation of enzalutamide due to the persisting inducing effect upon discontinuation of a strong inducer.
- f** Consider increasing raltegravir dose to 800 mg twice daily when coadministering with enzalutamide. Coadministration of once daily raltegravir is not recommended. Enzalutamide has a long half-life (5.8 days), therefore the raltegravir dose should be kept at 800 mg twice daily for a minimum of 2 weeks (but preferably 4 weeks) following cessation of enzalutamide due to the persisting inducing effect upon discontinuation of a strong inducer.
- g** Coadministration may decrease absorption of tenofovir alafenamide. However, intracellular tenofovir-DP concentrations are still expected to be higher than those achieved by standard dose tenofovir-DP alone.
- h** Poor tolerability has been observed in patients on ritonavir-containing regimens. (A similar effect may also occur with cobicistat-containing regimens).
- i** Concentrations of parent drug increased but concentrations of the active metabolite decreased which may result in decreased efficacy.
- j** Concentrations of parent drug decreased but concentrations of the active metabolite increased.
- k** Coadministration not recommended due to the potential for an increase in exposure and toxicity of DM1 (an active component of emtansine).